Protagonist Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) announced that CEO Dinesh V. Patel, Ph.D., will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 2:00 p.m. EST. The event will be available via live and archived webcast on their website. Protagonist is a clinical-stage biopharmaceutical company focusing on peptide-based therapeutics, with candidates like PTG-300 and PTG-200 in Phase 2 trials for various conditions, including polycythemia vera and Crohn's disease.

NEWARK, Calif., Jan. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021, at 2:00 p.m EST.

A live and archived webcast of the event will be available in the Investors section of the Protagonist Therapeutics website at https://investors.protagonist-inc.com/.

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. PTG-300 is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. Two additional oral peptide interleukin-23 receptor antagonist candidates are in development: PN-235, in a Phase 1 study, and PN-232, in the late preclinical stage. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in a Phase 2 study for the potential treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication. The Company utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms.

Protagonist is headquartered in Newark, California. For further information, please visit www.protagonist-inc.com. 

View original content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-39th-annual-jp-morgan-healthcare-conference-301199869.html

SOURCE Protagonist Therapeutics, Inc.

FAQ

When is Protagonist Therapeutics presenting at the J.P. Morgan Healthcare Conference?

Protagonist Therapeutics will present at the J.P. Morgan Healthcare Conference on January 11, 2021, at 2:00 p.m. EST.

Who is the CEO of Protagonist Therapeutics?

Dinesh V. Patel, Ph.D., is the President and CEO of Protagonist Therapeutics.

What is the focus of Protagonist Therapeutics?

Protagonist Therapeutics focuses on developing peptide-based therapeutics to address unmet medical needs.

What clinical trials is Protagonist Therapeutics currently conducting?

Protagonist is conducting Phase 2 trials for PTG-300 for polycythemia vera and PTG-200 for Crohn's disease.

Where can I watch the Protagonist Therapeutics presentation?

The presentation will be available via live and archived webcast on the Protagonist Therapeutics Investors website.